Entering text into the input field will update the search result below

Amgen initiated with a buy at Goldman Sachs; sees 27% upside

Dec. 06, 2021 12:31 PM ETAmgen Inc. (AMGN) StockBy: Jonathan Block, SA News Editor4 Comments

Amgen headquarters in Silicon Valley

Sundry Photography/iStock Editorial via Getty Images

  • Goldman Sachs has initiated Amgen (AMGN +3.1%) with a buy rating due to its inflammation franchise, expanding oncology portfolio and biosimilar business.
  • The firm has a $258 price target (~27% upside).
  • Analyst Salveen

Recommended For You

About AMGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AMGN--
Amgen Inc.